The past, present and future of tuberculosis treatment

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Dec 25;51(6):657-668. doi: 10.3724/zdxbyxb-2022-0454.

Abstract

Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including katG mutations in isoniazid resistance, rpoB mutations in rifampin resistance, pncA mutations in pyrazinamide resistance, and gyrA mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, Mycobacterium tuberculosis may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of Mycobacterium tuberculosis is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

Keywords: Diagnosis; Resistant tuberculosis; Review; Treatment; Tuberculosis.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics
  • Humans
  • Isoniazid / pharmacology
  • Isoniazid / therapeutic use
  • Mutation
  • Mycobacterium tuberculosis* / genetics
  • Pyrazinamide / pharmacology
  • Pyrazinamide / therapeutic use
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Tuberculosis* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / microbiology

Substances

  • Pyrazinamide
  • Isoniazid
  • Antitubercular Agents
  • Rifampin

Grants and funding

国家传染病医学中心——张颖启动经费(B2022011-1);济南微生态生物医学山东省实验室课题(JNL-2022050B);国家重点研发计划(2021YFC2301800);国家感染性疾病(结核病)临床医学研究中心项目(2020B1111170014);广东省高水平临床重点专科项目(SZGSP010);上海市市级科技重大专项(HS2021SHZX001);上海市科学技术重大项目(21NL2600100,20dz2260100)